CapsuleTech will integrate Masimo's oximetry technology into its latest SmartLinx patient-monitoring system
CapsuleTech is partnering with Masimo (NSDQ:MASI) on its latest SmartLinx patient-monitoring system, company officials said.
Ferolyn Powell, the former CEO of Evalve who led it to a $410 million acquisition by Abbott, is killed in a motorbike accident in Thailand.
Former Evalve CEO Ferolyn Powell, who led the MitraClip developer to a $410 million acquisition by Abbott (NYSE:ABT), died this month in a motorbike accident in northern Thailand, her family said yesterday.
, Cantel Medical Corp.
, Clayton Dubilier Rice
, InVivo Therapeutics Corp.
, JP Morgan Chase
, NxThera Inc.
, Spectranetics Corp.
, SurModics Inc.
, Urologix Inc.
, Abbott Laboratories
Masimo scored in 2014 with huge gains in both product revenue and net income.
Masimo (NSDQ:MASI), reported double-digit growth in sales and solid gains in net income during the final quarter of 2014.
Officials at the Irvine, Calif. -based patient monitoring company said they expect that growth to continue into 2015, even though foreign exchange rates will take a bite out of revenue over the coming year.
Medical device executives and Rep. Erik Paulsen (R-Minn.) scoff at a government report saying the levy's impact will be limited, telling MassDevice.com they're more confident than ever about repealing the medical device tax.
Medtech executives last week bashed a newly updated report from the Congressional Research Service refuting claims that the medical device tax kills jobs and hampers innovation.
An interview with medtech entrepreneur Joe Kiani, CEO of Masimo Corp. and the founder of the Patient Safety Movement Foundation, recorded at DeviceTalks West Nov. 19, 2014.
MassDevice.com publisher Brian Johnson sat down with Masimo (NSDQ:MASI) CEO Joe Kiani at DeviceTalks West in Irvine, Calif., On Nov. 19 for a wide-ranging interview about patient safety, corporate culture and the company's 25th anniversary.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Valeant Pharmaceuticals
, Allergan Inc.
Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?